Interactive Transcript
0:02
Hello, and welcome to Noon Conference hosted by Medality.
0:06
Noon Conference connects the global radiology community through free live
0:10
educational webinars that are accessible for all, and is an opportunity to learn
0:14
alongside top radiologists from around the world.
0:18
Today, we are honored to welcome Dr.
0:20
Doris Lin for a lecture entitled "Introduction to Clinical Brain Proton
0:25
Spectroscopy." Dr. Lin is a professor of radiology at the John Hopkins University
0:30
of Medicine and an attending neuroradiologist at the Johns Hopkins Hospital, where
0:36
she specializes in diagnostic neuroimaging.
0:39
She's been involved in the clinical and research use of advanced MRI techniques,
0:44
including spectroscopy imaging. At the end of the lecture, please join Dr.
0:49
Lin in a Q&A session where she will address questions you may have on today's
0:53
topic. Please remember to use the Q&A feature to submit your questions so we can
0:57
get to as many as we can before our time is up.
1:00
With that, we are ready to begin today's lecture. Dr.
1:03
Lin, please take it from here.
1:06
Well, first of all, welcome. This is a little bit of an esoteric topic on
1:11
spectroscopy, but hopefully in the next 45 to 50 minutes, I could give
1:17
you a glimpse of what we use in clinical spectroscopy,
1:23
particularly in the central nervous system in the brain.
1:27
So clinical MR spectroscopy actually has been used for a long time.
1:31
It was first approved by FDA in 1992.
1:37
Three years later, there was an automated spectroscopy that was implemented on the
1:42
commercial scanner, the GE at the time, and that has the name of a probe.
1:47
And in 1998, there was an approved CPT diagnostic code
1:53
that allows this procedure to be billed and reimbursed.
1:58
And that actually gets covered by Medicare and a number of insurance companies.
2:04
But fast-forward to 2001, that was 20-plus years
2:09
ago, American College of Radiology and CMS actually
2:14
put a commission together and performed a study of our literature review and
2:18
determined that spectroscopy
2:22
could only be used as an investigational tool, which does not meet
2:27
evidence-based medicine criteria, which is quite a blow.
2:31
And in 2004, Medicare and a number of insurance companies followed suit and just
2:37
declared that this is an investigational tool, and it will not be covered.
2:43
Not until very recently, 2021, and everything's sort of kept it quite
2:48
silent. But there was actually a retirement of this declaration of a national
2:54
coverage determination for spectroscopy. What does that really mean?
2:57
It means that in certain cases, it actually,
3:03
indeed, whenever it's performed for a clinical indication, you actually could
3:09
get reimbursed by a number of insurance companies.
3:15
During throughout this time, the past 20 years when it was not reimbursed,
3:22
actually, spectroscopy was very alive and well.
3:26
There are a lot of research developments, and it also used clinically, and that is
3:31
actually demonstrated on this very nicely written review article in
3:37
radiology. And I want to highlight and draw your attention to this.
3:41
They conclude, abstract summary, saying that the usefulness is demonstrated
3:47
and very well established for a number of indications, including brain neoplasms, a
3:53
number of neonatal and pediatric disorders, particularly HIE, inherited
3:58
metabolic disorders, and other
4:03
conditions, particularly differentiating neoplasm from non-neoplastic inflammatory
4:09
lesions. And this is actually the recent
4:15
page available from the website published by Blue Cross Blue Shield and as a
4:20
medical policy. I want to highlight that here actually shows that they
4:25
are considering spectroscopy as clinically appropriate when
4:31
it actually could be used for a number of indications.
4:35
This actually expands to quite a few areas, but it's very similar to what we have
4:40
known about in terms of neoplasm, distinguishing recurrent brain tumor from
4:45
radiation necrosis, and inborn error in metabolism we often see in
4:51
white matter disorders, pediatric central nervous system abnormalities.
4:56
So I think that is always considered a high-yield application for
5:02
spectroscopy. But also, just in general evaluation of neoplasms, grading,
5:08
and distinguishing from other infectious or inflammatory etiologies and even
5:13
epilepsy. Those are actually deemed appropriate and can be covered by insurance.
5:20
With all that said, so what is an MR spectroscopy?
5:24
Well, this is something that we use the same MRI scanner.
5:29
But MRI, MR imaging, what we do is to actually
5:35
get the proton signal that is spatially
5:42
mapped into imaging by the variations of the frequency and phase.
5:48
Spectroscopy, on the other hand,
5:51
is something that produces sort of squiggly lines such as this, that we call
5:55
spectrum, MR spectroscopy, that has a lot of peaks and values,
6:01
and we actually assign those peaks into different metabolites.
6:05
So practically, it gives you a biochemical composition or
6:10
information of that area that you have selected from the voxel area of
6:16
interest. So this is totally different from MRI, but it actually offers some very
6:21
unique information that is not afforded by your routine MR imaging.
6:29
So on the x-axis, we have this ppm, parts per million scale.
6:35
That is used to identify a peak location, and that is also--
6:40
this is basically by the difference of two frequencies of two different peaks
6:46
divided by the operating scanner frequency in hertz.
6:51
And here by definition, we have NAA, which is an N-acetyl
6:57
aspartate defined at 2.02 parts per million.
7:02
Know that we use this as a reference because if you remember from your chemistry,
7:07
we do do MR.
7:10
Then that is a spectrum of a solution in test tube, and usually the reference is
7:18
methyl tetrazoline. But that is, of course, not present in the
7:24
normal brain or any of the tissue that we have.
7:28
So this is to serve as a reference and just give you a sense of what kind
7:34
of
7:36
quantity or concentration that we see.
7:38
Most of the metabolites, those chemicals that we see in the brain,
7:44
is actually in a very, very small quantity, ranging from 0.5 to 10
7:50
millimolar, that kind of concentration.
7:53
And if you compare to water, water has two protons, but then water is
7:59
in the concentration of 110 molar range,
8:05
and that is sort of at least 10 to the 4th or 10 to the 5th
8:11
magnitude greater than any of the metabolites that we're actually interested in
8:17
looking at.
8:20
Okay, so with that, you might say, "Well,
8:25
so how do we do this?" That is something that it is very important in spectroscopy,
8:28
is that water resonance is actually at 4.7 parts per
8:34
million. In addition to during the acquisition we suppress, we actually saturate
8:39
the water signal. We also just cut off the display beyond 4.5 parts per
8:45
million so that we could actually see those tiny amounts of metabolites in this
8:51
spectrum and display here
8:54
And as a reference, in terms of sensitivity of any of the chemicals that we could
9:00
detect using spectroscopy, I list the sensitivity that you might be able
9:06
to get from SPECT or PET. Of course, those are actually very, very
9:12
sensitive and really the true molecular imaging.
9:16
And then you also use radio-labeled ligands and receptors and the tracers to
9:21
actually detect that. But the beauty of spectroscopy is that you could perform in
9:25
the same scanner without any radiation, without any additive agents, and then you
9:31
get this kind of information from the scan.
9:35
The information that you could get, proton spectroscopy,
9:40
is simple here. Listed here, you have three major
9:44
metabolites that we see: NAA, creatine and choline.
9:50
NAA, or N-acetyl aspartate, is heavily present in axons, neurons, the
9:56
cell bodies, and neuronal processes.
9:58
So that is a great marker for neuronal quantity and health.
10:03
So if there's anything that destroys the neurons, whether it's atrophy or
10:09
ischemia and/or the dysfunction, you actually see decrease of
10:15
NAA. So this is a wonderful marker.
10:18
Creatine is a combination of creatine and phosphocreatine, and those
10:24
are the molecules that you know that
10:28
represent energy metabolites and that is also present.
10:31
A lot of time we consider it somewhat constant within the brain tissue, or at least
10:36
in the
10:39
voxel selection that we use, and that is actually present at 3.0 parts per
10:45
million.
10:46
And there's a sort of a downstream in choline is
10:53
immediately you could see that this is a membrane constituent.
10:58
So any process due to abnormal rapid membrane
11:04
turnover, cell turnover because of neoplasm or inflammation with the
11:09
destruction of the membrane, you could actually expect to see the elevation of
11:14
choline. So glial cells and demyelination and those are things that are seen.
11:20
And also in pathologic conditions, you could also detect lactate.
11:24
Lactate has a classic appearance. This is a rabbit ear.
11:29
Rabbit is sort of due to J-coupling of this
11:34
proton, and they split into a distinct distance that is varied by seven hertz,
11:41
and that is present at 1.33 parts per million.
11:46
Whenever you have anaerobic glycolysis, ischemia change,
11:51
or bioenergetic failure, you can actually see that the lactate is
11:58
elevated.
11:59
So that's simple enough. And then you have additional metabolites that we're
12:04
calling minor metabolites we could actually see in the short echo time.
12:09
And that is when you obtain at the TE less than 35
12:15
milliseconds. That includes myo-inositol, which is present in glial cells and
12:20
astrogliosis, glial proliferation, and more of that.
12:24
You also have osmolyte within the brain.
12:31
Here to the
12:34
downside of the shoulder of the NAA, you have a combination of glutamate, which is
12:39
an excitatory neurotransmitter, and glutamine, which is amino acid, as a storage
12:45
form of glutamate, and that also can be determined.
12:51
And finally, in this range of 0.5 to 1.3 parts per million, there are also lipids.
12:57
So this is sort of additional small metabolites in addition to the major ones that
13:02
you could see when you actually select a different echo time.
13:07
Now, this lists a number of other compounds that you actually could identify,
13:13
including the ones that if you look very closely, particularly if you could see at
13:19
high magnetic field strength that have a better separation.
13:23
And the very small number of compounds, including very
13:28
great interest of GABA, if you do editing techniques, you can actually see that.
13:33
And then a number of things are listed here in pathologic conditions such as
13:39
ketogenic diet, ketosis, or
13:44
phenylketonuria. And finally, I'm going to also touch upon 2-HG is
13:50
onco-metabolite that we actually could identify using spectroscopy.
13:54
Finally, exogenously administered dilantin
14:00
byproduct and alcohol you could also identify.
14:06
So how it is done. Let's move on to that.
14:10
So this, as I said, is done in the same MRI scanner whenever you have the
14:16
commercial scanners, but then it requires a license to have an MRI spectroscopy
14:21
package available. And it could certainly be done in
14:25
any of the clinical strengths of 1.5 tesla or
14:31
3 tesla.
14:34
The two major localization techniques include a single voxel, which is easy to
14:39
perform, and also spectroscopy imaging that sometimes you might hear that's
14:45
multi-voxel. You could also call it MRI spectroscopic imaging or
14:51
chemical shift imaging.
14:54
Single voxel is widely available, easy to perform.
14:58
You could use a short echo time, and then you get lots of compounds that could
15:02
offer you some indication. Usually, you get a voxel size of four to
15:08
eight, ideally eight
15:11
cubic centimeter. The drawback is that only a few brain regions can be interrogated
15:16
at each time.
15:18
But this is simple enough to do that.
15:21
And the typical protocol we use a PRESS, point resolved spectroscopy.
15:25
Spectroscopic imaging, I'm not going to show today.
15:28
I would say that it is less available, but certainly can be done in many of the
15:32
commercial scanners. The processing is much more intensive, but
15:38
the advantage is that it provides you lots of different areas to interrogate.
15:45
The nominal voxel size is much smaller, meaning that you have less of volume
15:50
averaging artifact. It gives you much better brain coverage, so anything that is
15:56
heterogeneous, such as a glioblastoma with the enhancing tumors and
16:02
necrosis in the surrounding infiltrating tumors, this is actually the best
16:08
technique if you could afford doing that.
16:12
This is the pulse diagram, just to show that the two
16:17
major protocols for single voxel localization of the PRESS, point resolved
16:21
spectroscopy, and also STEAM, stimulated echo.
16:26
This is by 90, 180, and 180 degree pulses.
16:31
And in general, PRESS is much frequently used because this produces a
16:37
signal-to-noise ratio almost twice as much compared to STEAM.
16:41
And here, just to give you a sense what multi-voxel is like.
16:45
So here, instead of a tiny area of a voxel area interest, you get a volume
16:52
of interest here. We start with the chemically selective saturation
16:57
pulse to get rid of the water signal, and then localization in three different
17:02
gradients. And then here we actually produce lots of little grids of each of those
17:07
voxels. You can actually put a cursor and get a spectrum.
17:11
So you get a lot of information from this volume interest, but of course, it takes
17:15
a longer time, and as I said, it is a lot more demanding for the
17:20
technologist to perform and also for anybody to process it.
17:26
So our role as a radiologist,
17:30
how do we actually do that? Of course, we wanted to see
17:36
when it is indicated and what kind of information we want to
17:42
extract from that, right? And then in terms of technique and how the major
17:47
decisions come into determining, first of all, whether you want to do single voxel
17:53
versus multi-voxel ... selection of a TE, the echo time, the
17:59
short one versus intermediate 140, or twice of that at 280
18:04
milliseconds. And as I alluded to, you get a lot more information,
18:10
minor metabolites from the short TE exam.
18:14
But long TE exam, you actually get very clean-cut peaks and actually
18:20
get some essential information if that is all you needed.
18:24
And then you just need to choose where you want to interrogate.
18:28
If there's a lesion, you should always get a contralateral normal brain as a
18:32
control. And in the voxel size, ideally you get large
18:38
enough voxels so that you get enough of the time, enough the signal to actually
18:43
produce a meaningful spectrum that you can interpret.
18:48
In terms of analysis, all the scanners actually provide post-processing, and then I
18:53
think the technologists actually produce that and then send it to your scan so you
18:58
can actually do that. A lot of time when we're reading this, we actually just do
19:03
qualitatively. In research field, and any time you wanted to be more precise or see
19:09
subtle changes, yes, there are some quantitative softwares that you could do the
19:14
post-processing, but you doing clinical use is very similar to reading a MRI
19:20
scan that I interpret mostly qualitatively, but also in
19:25
conjunction with the MRI itself and the clinical information.
19:30
That is important to note. This is an example that if you have a focal
19:35
lesion, for example, this in the right middle cerebral artery, you have a FLAIR
19:39
hyperintensity, a little expansile. You put a voxel there, and that is your lesion.
19:45
You get a spectrum, and then put a contralateral voxel, the
19:51
same volume, and then just put it over there, and then you get another
19:57
spectrum. So that is easy to compare with a single voxel.
20:01
Whenever there's no focal lesion, I still choose two different locations just to
20:06
get representation from different gray matter versus white matter.
20:11
One is the thalamus, deep gray. Sometimes you could also include the basal
20:16
ganglia. And another voxel is placed in the largest area that
20:22
you could find a white matter that is without getting into the volume averaging
20:27
artifact. So here is placed in the central semiovalie.
20:31
You could do the left or right because there's no focal lesion that's identified.
20:36
So that is my approach.
20:39
But this is actually sort of an exception, special scenario.
20:44
If you are concerned about hepaticity, you know that this is a reversible delirium
20:49
process. Yes, you very simply place a single voxel, but you have to
20:55
use a TE of a 35, 30 milliseconds, a short TE.
21:01
And you use the mesial paraxial gray matter and then another voxel in the white
21:06
matter to get a different sampling of the gray versus the white.
21:11
Why do we do this? Because this is the scenario that you have accumulation
21:17
of a number of neurotoxins from hepatic failure, and then
21:23
we are relying on short TE to see the elevation of a glutamine. Okay.
21:30
This is some tips. If you cannot find the lesion very well, yes, it is okay
21:36
to add the spectroscopy after you have performed the MRI
21:42
and have given contrast. It does not really affect metabolic levels.
21:47
And in general, if somebody who does not have the kind of patience to hold still
21:53
for that duration, that takes quite a few minutes for spectroscopy interrogation.
21:59
Single voxel is much faster and less motion sensitive, so go with that.
22:04
If major metabolites are the primary concern, you don't really need to get a short
22:09
TE. So I think that the long TE press protocol works very well.
22:15
A lot of time, I love the intermediate 140 milliseconds TE because in
22:21
that
22:25
you see the lactate being inverted and then that's distinguished from many other
22:29
metabolites that could be there, such as lipid. However, this is a note of caution.
22:34
At 3 Tesla, which is very widely available these days as a clinical scanner.
22:40
However, because the chemical shift dispersion, the TE 140,
22:46
intermediate TE, actually could now produce a pitfall because the lactate
22:52
gets sort of obscured. So if that is the primary concern, primary question,
22:58
avoid 140.
23:01
Another pause. I think this is quite a bit, but I think this is just a technical
23:06
aspect. So my default protocol that I do clinically at
23:11
Hopkins is a single voxel using PRESS, two by two by two centimeter ideally,
23:18
because if it is smaller, you actually get a lot of noise.
23:22
And use the two TEs, short and long, but know that I bypass 140 milliseconds to
23:28
go immediately to 280, and in two locations. Okay.
23:36
So I hope that you get from this latter half of this talk,
23:42
you see that how it is applied in clinical practice.
23:45
I think I want to convince you that it can be very useful in the diagnosis,
23:49
prognosis, and treatment response monitoring.
23:53
And I will show some examples, including ischemic
23:58
conditions, metabolic disorders, particularly in pediatric population, and
24:04
also the one that we actually could take more advantage of
24:10
is the tumor characterization. Not so much for primary diagnosis, but distinguish
24:15
neoplasm from non-neoplastic processes, and also radiation necrosis versus a
24:21
residual tumor. And also finally, the new onco-metabolite.
24:25
I think spectroscopy is going to make a difference in terms of how we practice.
24:31
So here we have a spectrum in a full-term newborn presenting with neonatal
24:37
seizures.
24:39
This is a T1-weighted image that's not going to show a lot that you might say, "Oh,
24:43
well, it's most watery." But putting a voxel over there, and this is a metabolic
24:48
map, you could see that there is elevation of lactate.
24:51
The spectrum shows this beautifully inverted doublet that's a classic lactate that
24:56
you see in TE of 140 milliseconds.
25:00
This is a choline. It is high, and NAA may be low, but know that in
25:06
a newborn, choline is actually dominant peak.
25:11
And we will revisit that. But this actually by assignment based on the
25:16
location parts per million, you can actually know what they are.
25:21
And this is indeed hypoxic ischemic injury that they're presenting with this, and
25:26
the lactate is a classic signature.
25:29
A number of studies have been performed quite a while ago, and it demonstrated that
25:34
MR spectroscopy is very, very sensitive to metabolic changes such as a hypoxic
25:40
ischemic injury. These days, we heavily rely on diffusion-weighted image for those
25:44
to identify those abnormalities, but know that in neonates,
25:50
the peak of HII or diffusion changes may not be apparent until
25:56
three to five days after the initial insult, and then it rapidly
26:02
reverses. But spectroscopy is actually sensitive immediately within 24 hours and
26:07
also
26:09
a lot of time you undergo after the acute event, you have a secondary energy
26:14
failure after reperfusion, and that is another time that you actually capture
26:19
marked elevation of lactate, which becomes the best signature.
26:26
With a prolonged hypoxia or ischemia, we could also gradually see NAA decreases.
26:32
And this study, this paper presented 20 years ago, actually showed that
26:38
the NAA concentration as well as the ratio of lactate to NAA could actually predict
26:43
outcomes. Here, I want to draw your attention again to remember that a normal
26:48
infant choline is at the highest peak.
26:51
And with this baby, with a small amount of lactate, actually turned out to have a
26:57
mild outcome and then could do favorably.
27:00
However, if you have the huge whopping amount of lactate and a decrease in NAA,
27:04
that typically corresponds to a severe outcome
27:08
Here is a five-year-old with a complicated history of adrenal insufficiency,
27:13
actually rely on hydrocortisone every night to sort of boost up the adrenal
27:18
function. But after missed one dose, presented something like this, a change of
27:24
mental status. FLAIR shows wide entire left hemisphere, but very
27:29
much isolated to the gray matter. FLAIR hyperintense, reduced ADC,
27:36
but DSC perfusion mean transit time is actually you have a fast arrival
27:42
of a blood to this area, and that also confirmed that you have increased cerebral
27:46
blood flow to the left hemisphere on ASL perfusion. So what is happening?
27:52
Now, spectroscopy actually shows that, wow, this is a
27:57
140 TE and lactate inverted beautifully shown, and then at a
28:03
short TE of 35 or 30, you actually operate here.
28:08
There's definitely indication of a bioenergetic failure.
28:12
So this is actually most likely a phenomenon due to
28:18
glucose being low, and you may consider metabolic stroke.
28:23
Or another scenario is that this is sort of a part of the routine response to
28:29
metabolic anomaly. You actually have seizure activities, and it's showing this kind
28:34
of appearance.
28:37
In metabolic disorders, a lot of important area of metabolism, you could expect
28:42
that spectroscopy could be very helpful, and it sort of has a distinct signature.
28:47
This is a three
28:49
and a half month old infant. Has some symptoms that are like seizures.
28:55
Pediatrician also noted that it's a pretty accelerated head circumference
29:01
growth, so big head. Here on MRI T2-weighted image, of course, everything's still
29:06
very watery, but here, definitely a lot of hyperintensity in the occipital white
29:12
matter and thalamus. Thalamus definitely abnormal signal.
29:17
So here, a voxel placed in the thalamus.
29:21
On the first glance, you may say, oh, the Hunter angle and the AA creatine
29:27
choline looks great, right? But remember that this is a young infant.
29:32
You do not expect to have such a high NA.
29:36
So this is indeed a signature, and it makes a beautiful diagnosis of
29:41
Aicardi-Goutières disease. Rare disease, but
29:46
very poor prognosis, and this actually nails the diagnosis very nicely by
29:52
in vivo spectroscopy.
29:55
There's another rare case.
29:58
Note that spectrum-- well, this is probably short TE.
30:02
You have a lot of ammonium metabolites, but here you have NA.
30:07
But here we seems to be missing something.
30:10
So after treatment, then you actually see the peak of creatine.
30:15
So this is a rare disease of agynine, creatine deficiency.
30:20
The enzyme deficiency could be treated by supplement.
30:27
So that is actually first demonstrated in the paper.
30:31
This is a graph from this review article in Radiology, but there are additional
30:36
references that actually talk about the identification by using spectroscopy, the
30:41
mechanism, and also the treatment response, and a very beautiful way
30:47
that to non-invasively and longitudinally follow therapy, and then in addition to
30:53
making a diagnosis.
30:56
Here I have a... This is one of the clinical cases I've encountered.
31:00
Four-year-old with sort of a scaly, like a fish scale, that kind of a skin changes,
31:05
very rough skin, development delay, and spasticity.
31:08
So almost like a classic clinical triad.
31:11
Has some white matter signal abnormalities, very non-specific.
31:15
What do we see on spectroscopy? So here, we actually single voxel in a
31:20
non-focal lesion matter. So one placed in the thalamus, the other one in the
31:25
central semiovalley. But both actually show that there is abnormal peak
31:31
at 1.3 parts per million without a doublet. So what is it?
31:36
This is classic location of a methylene group of a lipid,
31:42
and that confirms the clinical diagnosis of
31:46
Sjögren-Larsson syndrome.
31:50
Now, this is another rare inherited autosomal recessive genetic condition.
31:55
Of course, the diagnosis could also be made by genetic
31:59
testing. But here it actually just beautifully show that because an
32:05
important area of lipid metabolism of microsomal enzymes, it has a deficient fatty
32:11
aldehyde dehydrogenase producing those mobile lipid we could actually
32:16
identify from
32:19
just putting a voxel on the clinical exam.
32:24
Finally, an older person, 56-year-old, no other medical conditions,
32:30
although a remote history of some kind of a transient loss of consciousness.
32:36
Now presenting with vision loss
32:39
for almost eight days. Did not present until eight days later
32:45
with this kind of MRI flair hyperintensity in the right occipital lobe, definitely
32:51
involving the visual cortex, and very subtle
32:56
area of decreased diffusivity. But again, this is a sort of strange pattern for
33:04
infarct, right? And it's also isolated.
33:06
This is not your classic PCA infarct, but it certainly acts a little like that.
33:12
So a little bit four months later, presenting again, the right side of the
33:18
abnormality is evolving to atrophy, encephalitis, and then there's a new
33:24
abnormality extending into the left occipital as well
33:30
as the parietal lobes. And this probably corresponding to the focal motor
33:36
seizure affecting the right arm, the clinical presentation.
33:39
So this is the imaging appearance.
33:43
Immediately, you're talking waxing, waning, shifting that kind of signal
33:47
abnormality involving the cortex, right?
33:50
And looking like a seizure or a stroke-like thing. So what is it?
33:55
Spectroscopy is performed at the time.
33:58
What we do see is much elevated lactate. Note that doublet.
34:04
This is a
34:08
long TE, this is short TE exam, but both actually showed that very high
34:13
lactate, and that is classically seen in conditions like this of
34:19
mitochondrial disorder. It took another three months.
34:23
The person come back again with multiple other shifting areas, without
34:30
necessarily any restricted fusion.
34:33
Finally, deltoid muscle biopsy showed ragged red
34:39
fibers, which nails the final diagnosis of MELAS.
34:44
But from the clinical presentation, MRI imaging, and spectroscopy, you could
34:49
actually have made that brilliant diagnosis as well.
34:53
This is a mitochondrial dysfunction and causing this kind of a metabolic stroke, if
34:58
you like to call that.
35:03
The next
35:06
part, I'm actually going to touch upon tumor.
35:08
This is a big field, and it's quite dense, so I have to speed up a little bit.
35:13
So spectroscopy and tumor.
35:16
This is a nice diagram
35:19
put in this nature review. Choline is a product that
35:25
we actually major contribution from our diet.
35:30
But in the presence of a tumor, there's also-- well, and then this actually get
35:36
converted into a lot of membrane constituents, phosphatidylcholine, and
35:41
lysophosphatidycholine, et cetera.
35:45
But in cancer
35:48
pathology, there are a number of activation enzymes that shifts to
35:54
have elevated production of a number of products, including choline,
36:00
phosphocholine, and glycerol phosphocholine.
36:04
So those actually become a very useful marker for neoplasm, particularly
36:11
more malignant, very cellular ones.
36:14
If you have a tumor cell hypercellularity, here is a plot
36:20
of cell density actually nicely have a very nicely linear
36:26
proportion to the
36:29
the concentration of choline. And that is deriving from lots of different
36:34
pathologies, including oligodendro, sort of high-grade
36:39
glioma, low-grade oligodendroglioma, astrocytoma, and GBM.
36:45
GBM, remember that a lot of the time the cell actually becomes less dense because
36:49
of synchronicosis after stripping the normal blood supply, et cetera.
36:56
Here is one example of signal abnormality. A little bit faint contrast enhancement.
37:02
Diffusion trace image actually shows some areas of hypercellularity as indicated
37:08
by sort of decreased ADC values. On MR spectroscopy, you can
37:14
sort of see that in this lesion,
37:18
the marker of choline is much elevated. NAA is low.
37:24
And of course, we always wanted to have a contralateral site as a control.
37:30
You could see that as a normal display of NAA being the highest, if you want to
37:34
call it a hunter angle or not, and this is completely reversed, right?
37:38
So this is
37:41
basically the classic appearance of a neoplasm.
37:46
And this actually is still a low grade, but it's an oligodendroglioma,
37:52
very hypercellular, and that is reflected nicely on this case.
37:58
We don't really use spectroscopy as a primary means of making a
38:04
diagnosis of brain tumor. However, it has a lot of signatures that are worth
38:09
reviewing and understanding. These days, of course, all the tumors get biopsied,
38:14
then resected, and you have final pathology.
38:17
But I think this also helps us to determine what we might be able to glean from
38:23
spectroscopy as added information.
38:25
So here I have the spectrum of the parietal white matter.
38:28
This all come from this study by Hao et al.
38:32
NAA being at top of this is a short echo time, so you get a lot of metabolites as
38:37
well. Know that grade two astrocytoma, it is characterized by
38:42
higher choline level, lower NAA, but most notably you have elevation
38:48
of myelin oso. Remember that this is actually your glial marker, astroglial
38:54
proliferation that is most abundant in even low grade astrocytoma.
39:00
As the grade shift should be higher to the anaplastic, this may still be elevated,
39:06
but you actually start to see more of a lactate and lipid.
39:10
And then finally shifting to glioblastoma when you have synchronicrosis and normal
39:15
modular peripheral enhancement.
39:18
And this, you could see that a lot of normal brain metabolites
39:24
actually decrease, but then dominated by this lactate and lipid peak.
39:30
This kind of appearance becomes actually virtually indistinguishable from
39:34
metastases. Metastases, of course, you talk about secondary tumor.
39:39
We don't really see,
39:43
as opposed to the primary
39:45
gliomas, though the major metabolite is actually very low, but then it's marked by
39:51
a lot of necrosis and
39:54
lactate and lipid presence. So they actually look very similar.
39:59
And finally, meningioma is a neuroepithelial extra-axial tumor.
40:03
It has sort of something that's a sort of outlier, that kind of appearance, because
40:07
a lot of time people will actually see that the alanine gets elevated, but a lot of
40:13
time it get mixed in this pool of lactate plus lipid.
40:18
So using this, even limited number of different pathologies,
40:24
they were able to sort of plot this by looking at myelin oso to choline
40:30
ratio versus alanine, lactate, and lipid, and segregate into different
40:36
categories. Know that glioblastoma metastases very heavy on the peak of
40:42
lipid and lactate. They're nearly indistinguishable.
40:47
Whereas a primary glio tumors, astrocytoma, whether it's grade two or three, you
40:52
see elevated myelin oso. And of course, anaplastic astrocytoma, higher
40:58
grade, you actually also have more the presence of lipid and lactate.
41:04
And finally, meningioma falls into this lower corner that does not
41:10
really have any of the normal complements of the brain tissue, but
41:16
has elevation of alanine.
41:22
Here is a study of almost a clinical trial using machine learning and deep learning
41:28
from multiple sites in the European country.
41:32
And actually they plot and they start talking about the diagnostic accuracy.
41:36
They have 200 plus
41:39
training cases and 97 test cases. And they found that there was almost 90%
41:44
diagnostic accuracy in distinguishing most of the tumors versus
41:51
whether this is mets versus low grade,
41:55
or meningioma or GBM versus low-grade glioma.
42:00
However, the error rate or the lack of a diagnostic value is
42:05
the distinction between GBM and the mets.
42:10
So keep that in mind. A lot of time they look very similar in spectroscopy, whereas
42:16
the other ones, you can actually often use the spectrum information and then give a
42:22
reasonable diagnosis.
42:25
Here is an article from Dr. Barker.
42:27
It's from our institution, and this is actually comparing
42:33
MRSI and perfusion weight image to
42:38
separate malignant versus non-malignant brain lesions, whether it's a
42:44
low-grade tumor or inflammatory lesions.
42:48
And the ROC curve actually show that the discriminant function analysis show that
42:53
spectroscopy MRSI actually performed superiorly to
42:59
perfusion imaging alone. And that actually really offers a great value.
43:05
And those are a couple of values that use for analysis.
43:09
But of course, if you combine both perfusion and spectroscopy, you actually have
43:14
the superior performance here.
43:21
But in individual cases, how do we evaluate?
43:24
This is a case of a primary sinus lymphoma, edema, some patchy enhancement.
43:30
The CBV a little bit elevated, but choline elevation is a marker of a
43:36
neoplasm. As compared to this, also a lot of edema,
43:43
nondescript patchy enhancement.
43:45
CBV may be a little elevated here, but choline, creatine, NAA, everything's low.
43:51
So this is actually an example of a meningomyelocele.
43:54
It's very useful to distinguish that apart.
43:58
Now, I want to move into something that we have not moved to the clinical practice
44:02
yet, but this is emerging and very useful.
44:05
So 3-HG, as you know, hydroxyglutarate is a marker of IDH
44:11
mutations.
44:13
IDH these days defines a low-grade glioma, and it offers a diagnostic and
44:19
prognostic value, and also is a great therapeutic target.
44:24
A targeted therapy you can actually use to treat those people with a low-grade
44:29
glioma. And how does it, right? IDH is an enzyme that convert in
44:35
the TCA cycle from isocitrate to alpha-ketoglutarate, and that is a sort of a
44:40
non-mutated wild type. You actually have this just normal complements.
44:45
Whenever it's mutated, however, it produce a so-called onco-metabolite that is not
44:51
present in normal brain and not present in people without any
44:57
tumors. So that becomes a great signature. But why is it important?
45:02
Know that this graph from 2015, New England Journal of Medicine, you have a
45:06
survival curve, the Kaplan-Meier plot that of course, low-grade glioma with IDH
45:13
mutation, pretty good survival. And the best is the one with 1p19q
45:18
codeletion, which marks the oligodendrocyte.
45:23
And as opposed to the GBM, very poor prognosis, a very grim
45:29
outcome. But note this, this red line and the triangle, inverted triangle
45:35
is the histologically diagnosed low-grade glioma, but with the wild type,
45:41
without the IDH mutation. This is in the old days, diagnosis made purely by
45:47
histology. However, this survival curve is As grim
45:53
as the classic GBM.
45:56
And that also separate from this, the GBM, but actually these days we're talking
46:01
about IDH-mutated grade four tumor.
46:05
And this basically highlights the
46:10
subsequent revision of WHO classification from 2021
46:15
that by default, any tumor, even though it looks like low grade with
46:21
wild type IDH, automatically it is GBM.
46:27
So this is actually, in fact, developed. This is from Dr.
46:32
Choi from 2013 showing that with optimized spectroscopy using
46:38
TE of 97 milliseconds, you can actually separate this tiny metabolite of
46:44
2-hydroxyglutarate from the glutamate and glutamine.
46:49
And that could have an immediate impact in tumor locally in
46:55
the brainstem where biopsy is not possible or undesirable.
47:00
And here you actually can see. And also a great way to monitor disease
47:07
nowadays that we have approved targeted therapy available.
47:12
So this is a sort of emerging area, not yet widespread in these clinical practice,
47:18
but I do hope that this can be carried out.
47:24
I think I'm running out of time, but...
47:29
So Ashley, do you want me to go on? Or should
47:35
I sort of
47:37
wrap up?
47:41
You can feel free to wrap up and-
47:43
Okay
47:43
... take some questions if you'd like.
47:45
Sounds good. All right. I will skip this part, that I want to say
47:51
that spectroscopy has also made to the realm of
47:57
modifying the clinical practice and in causing a difference of
48:02
management. This is, you know that a lot of time you're talking about
48:07
diagnosis of a GBM. We use contrast-enhancing area to plan radiation
48:13
therapy. And that perhaps should be altered using
48:19
MS spectroscopic imaging where you could create a map, and the hot zone
48:23
demonstrates elevation of a choline to NAA ratio more than two.
48:28
So this is actually piloted in the study, a three-site study, that they basically
48:33
modify the conventional way of a radiation of this
48:39
clinical target volume of 60 gray and then a five-millimeter margin
48:45
and another five-millimeter margin as the standard care.
48:49
On top of that, they basically use spectroscopy to evaluate, to create a
48:54
new gross tumor volume and
49:00
boost the radiation dose to 75 gray.
49:05
So this was to really see if it's feasible and it's safe and then to
49:10
analyze the survival. So very quickly through this, I want to just go to the bottom
49:15
line, is that, yes, the clinically imaging-defined enhancing area,
49:21
the volume is actually small, average of a 1.58.
49:26
As compared to the new methods, it is a lot larger.
49:32
And with that,
49:34
the result is quite striking. The tumor recurrence, which often comes from
49:40
the resection margins, is actually reduced to 30% versus the standard care of a
49:46
60 to 70%. Of course, you have some sort of progression and some toxicities,
49:52
but it's not
49:55
unexpected, not excessive. And finally, in secondary
50:01
analysis, they show that the patients with a lower post-surgical choline-to-NAA
50:07
ratio has significantly superior survival outcomes.
50:10
Whereas if you just purely judge by the residual enhancement to guide
50:16
therapy, has little correlation or little significance in the progression-free
50:22
survival or overall survival. So this actually has been sort of
50:28
expanded to phase two trials, and I'm really eager to see that get into the
50:34
clinical practice.
50:36
Very fast, tumor necrosis, everything's down.
50:41
Recurrent tumor, you actually see elevation of the choline and the presence of
50:45
lactate. But know that a lot of time we have a mixed histology, and
50:51
however, know that the tumor to separate from necrosis, it is marked by those
50:57
at choline and lipid amount. But on individual cases,
51:03
it could be challenging. So astrocytoma,
51:09
a lot of post-treatment or the tumor cause edema, a little bit
51:15
enhancement. We also see a little bit in the contralateral side.
51:17
Spectroscopy
51:19
actually highlights that these areas are low metabolized.
51:24
That is just treatment change and edema.
51:26
Whereas this little area in the contralateral side, somewhat unexpected, actually
51:32
represents the presence of a tumor.
51:36
And this is actually confirmed aspect on a PET-CT.
51:40
Unfortunately, it was completely missed.
51:43
So those are things that to really keep in mind.
51:47
So finally, I get into the conclusion.
51:50
Hopefully, in this session, I can convince you that spectroscopy really is a
51:56
very useful technique. It allows a non-invasive evaluation of the brain metabolites
52:00
in vivo. It is easy to perform if you know how.
52:06
And then it really provides additional information that is not offered by
52:09
conventional MR by signal changes or even diffusion or perfusion, which
52:15
actually evaluate vascular density.
52:17
This provides a unique information about biochemical composition of the
52:23
tissue and the lesion. There are a number of wide range of clinical applications
52:29
that can be useful for diagnosis, prognosis, and treatment monitoring.
52:33
Hopefully, with this, you have a little understanding of when that may be
52:38
indicated, when you might want to incorporate into your practice, how to protocol,
52:45
and beginning to learn how to
52:48
provide your interpretation, add information, and
52:53
provide better value for clinical diagnosis.
52:58
That said, I want to acknowledge that I worked with Dr. Barker for a long time.
53:03
All this, I learned a great deal from him.
53:07
He does all the clinical processing, and then we have gone through the
53:13
discussion, and I'll provide the many of the slides and the information that I've
53:17
offered here. And I thank you for your attention.
53:22
Thank you for sharing your lecture with us today, Dr. Lin.
53:25
At this time, we will open the floor to any questions from our audience.
53:29
You may submit your questions to the Q&A feature. And Dr.
53:33
Lin, if you want to open up that Q&A box and look through the questions, see what
53:37
you want to answer.
53:39
Okay. So should I-- Okay, I will stop share, and I see in the chat
53:45
or-
53:48
There is a secondary Q&A box. It is hidden a little bit.
53:54
Okay. I got six. Okay. So the first one, why is the quality of a CSI voxel
54:00
degraded at the edge of the field coverage? Great.
54:03
You remember that chemical shift, basically, this is another name for
54:08
MRSI or multi-voxel. You are exciting a much larger area.
54:14
And spectroscopy, you're talking about it is very sensitive to field inhomogeneity.
54:19
You're exciting a lot of things. Whenever you are close to the scalp, that you have
54:25
a lot of lipid, and then that spills over, and then you grade the
54:30
area very prominently. That is also the reason that we meticulously
54:35
apply saturation bands on all the corners of the multi-voxel
54:41
planning. So that's a very good question, and the technical aspect that also
54:47
highlights the fact that it is very clinically challenging, but
54:52
then this is certainly doable.
54:56
From
54:59
Mahmoud Mourad. So why is spectroscopy used instead of other techniques such as a
55:05
biopsy? Well,
55:07
something that's obvious, yes, biopsy is always used for our final
55:13
diagnosis. However, the beauty of spectroscopy is that you get this information and
55:18
providing some diagnostic value without cutting open the brain,
55:24
the skull, and so it's completely non-invasive.
55:28
And if it could provide the genetic information prospectively, that could be very
55:33
useful. And I hope that I conveyed the fact that the 2HG,
55:39
to actually see the IDH-mutated tumor, that
55:45
is particularly important because sometimes they are located in the areas that you
55:49
don't want to biopsy or let alone complete resection. Right?
55:56
The second question is why are only three metabolites measured in spectroscopy?
56:01
Yes. That is when you're talking about a long echo time.
56:06
Those are measured metabolites that you could actually see.
56:11
You might say, "Oh, this is too few," but I showed you that there are many others
56:16
ones. I hope that is clear. It's more than that, but sometimes
56:22
just the three major metabolites and the changes, the ratio, and amounts could
56:26
actually provide you a lot of information.
56:29
And then it gives you a very clean cut spectrum.
56:32
And so I think a lot of time that is just as valuable.
56:36
But yes, you could get additional sort of shorter TE, get other minor metabolites.
56:42
And if you have the tool available shifting to seven Tesla ultra-high field,
56:48
you get even greater complement of metabolites information that
56:54
you could get.
56:56
So what is the predictive value? I think a lot of the things that the predictive
57:01
value, you could see that what I have shown you is very much coming from the
57:07
previous many other studies and group analysis.
57:11
So on the individual cases in clinical MRI, it still takes quite a bit of
57:16
experience and then learn how to sort of spot as a
57:22
qualitative manner. I hope that is also clear and that answer your questions.
57:28
Any role in spectroscopy in neurocognitive disorders?
57:32
Indeed, this is actually a very active field of investigation.
57:36
It has been applied to many different conditions. Alzheimer's is a hot topic.
57:42
Yes, we do see the elevation of some-- well, sometimes if you have
57:48
inflammatory components, glutamate, glutamine, particularly glutamate may be
57:53
elevated and the NA is down. But, I think those are
57:57
maybe subtle changes and then again, it requires sort of a more group, not just
58:02
individual, that kind of diagnostic value.
58:05
Any psychiatric disorders when MRI is completely normal, this actually has been
58:11
applied. Know that glutamate is excitatory
58:16
neurotransmitter. The fact that we can measure it, and it is sort of critical
58:20
during development and plays a role in cognition, memory, and
58:28
learning. So I think that definitely that gets altered.
58:33
It gets decreased in a number of neuropsychiatric disorders such as schizophrenia,
58:39
bipolar disorder, and OCD, et cetera.
58:42
So those are definitely very relevant areas.
58:48
And I think another question, Alzheimer's disease, yes, people do use that to
58:52
evaluate. It probably requires a lot more data to actually pull together to
58:57
actually show on an individual basis, rather difficult.
59:03
So Carla, I have one minute. Spectroscopy of GBM with all
59:09
metabolites low but lactate, and then how could you differentiate from radiation
59:12
necrosis? Yes. A lot of time there's a lot of overlap, and that is a difficulty.
59:19
I hope that from the later group analysis, you could sort of see that indeed
59:24
there's a lot of overlap. But detecting even the slightly higher choline
59:30
and the presence of lactate and lipid, that usually you
59:36
actually do see that it is a residual tumor or neoplasm over there.
59:44
Do you depend on spectrum of edema to differentiate single MET from GBM?
59:50
So that is something that you could utilize,
59:57
the difference between GBM and METS.
60:00
METs actually induce a lot of edema causing flare
60:05
hyperintensity. But GBM is an infiltrating glioma that the
60:10
surrounding flare hyperintensity actually indicates
60:16
tumor infiltration. So very often you could indeed use that to determine.
60:21
But that information is probably better answered if you
60:27
have access to a multi-voxel exam to look at the heterogeneity in that
60:33
larger field.
60:36
Okay. Anything else? What are the conditions where spectroscopy is not useful, for
60:41
example, in areas of bleed and those type of situations? Yes.
60:45
Vikram, thank you for that question.
60:48
I think in this talk, I specifically highlight the utility
60:53
of spectroscopy and where it could shine and it sort of
60:59
becomes a poster child of everything, right?
61:02
It sounds very wonderful, but there are a number of pitfalls.
61:06
Technically, it could be challenging analysis and all that.
61:10
As you said, where there's a lot of blood, blood causes susceptibility artifact,
61:16
distortion of a local homogeneity of the magnetic field.
61:19
Immediately, it's going to affect the way that you are going to get spectroscopy
61:25
done. Shimming is a
61:28
very important factor that you have to get good quality spectrum, and that is from
61:33
technical aspect. But if the lesion is too small in an unfavorable area such as
61:39
skull base, close to fat, scalp, orbit,
61:43
and in the presence of a bleed, a lot of time it could fail.
61:47
And then very often I do make the decision that I'm not going to attempt it because
61:51
it's going to be futile.
61:56
Okay, I think I answered all of them, right? But I also went over time.
62:01
Sorry about that.
62:03
No worries at all. Awesome job getting to all those questions.
62:07
Thank you for that lecture and for answering all those questions.
62:12
Okay. All right. Thank you. And if there's additional questions, if you
62:18
have any that actually you wanted to forward to me, I could also reply afterwards.
62:26
All right, great. Thanks to everyone for participating in our noon conference today
62:31
and asking all those great questions.
62:33
You can access the recording of today's conference and all our previous noon
62:36
conferences by creating a free account.
62:38
We'll also email out a link to the replay later today.
62:43
Be sure to join us next week on Thursday, September 24th at 12:00 PM Eastern, where
62:48
Dr. Pamela Kettwaru will deliver a lecture entitled Fetal MRI.
62:52
You can register for that at medallie.com and follow us on social media for updates
62:57
on future noon conferences. Thanks again, and have a great day.